Levosimendan Altan

Levosimendan, the active ingredient in Levosimendan Altan, is a calcium sensitizer presented as an intravenous formulation for intravenous use. It treats acute decompensated heart failure in adult patients by improving cardiac contractility without increasing intracellular calcium concentration.

GNH USA supplies Levosimendan Altan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Levosimendan is a calcium sensitizer used in the management of acute heart failure syndromes.

Acute decompensated heart failure: improves cardiac output and relieves symptoms in patients with sudden worsening of heart failure.

Levosimendan may be associated with a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Hypotension: drop in blood pressure, especially after loading dose. - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Tachycardia: increased heart rate.

Serious or Rare Side Effects: - Ventricular arrhythmias: potentially life‑threatening rhythm disturbances. - Severe hypotension: may require vasopressor support. - Allergic reactions: rash, pruritus, or anaphylaxis in rare cases.

Levosimendan requires careful monitoring and specific safety considerations before and during therapy. - Cardiovascular monitoring: continuous blood pressure and ECG observation. - Renal impairment: dose adjustment may be needed in severe dysfunction. - Hepatic impairment: use with caution in patients with significant liver disease. - Concomitant vasodilators: avoid excessive hypotension when combined with other vasodilatory agents. - Contraindications: do not use in patients with severe hypotension or critical aortic stenosis. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levosimendan can interact with other cardiovascular drugs, influencing its safety and efficacy.

Major Interactions (Avoid): - Other potent vasodilators: may cause severe hypotension. - Strong inotropes (e.g., dopamine, dobutamine): increase risk of arrhythmias. - CYP2D6 inhibitors: may raise plasma concentrations.

Moderate Interactions (Monitor Closely): - Diuretics: monitor electrolytes and volume status. - Beta‑blockers: may blunt desired inotropic effect. - ACE inhibitors/ARBs: watch for additive blood pressure effects.